Zubsolv vs Suboxone: Formulation and Dose Differences

Zubsolv and Suboxone are prescription medicines used in medication treatment for opioid use disorder. Both contain buprenorphine and naloxone, but their formulations, available strengths, absorption and practical use differ, so they should not be switched without guidance from the prescribing clinician.

Zubsolv vs Suboxone: side-by-side comparison

Zubsolv and Suboxone are both medicines for opioid use disorder (OUD) that contain the same two active ingredients: buprenorphine and naloxone. Buprenorphine helps reduce opioid withdrawal symptoms and cravings, while naloxone is included to discourage misuse by injection. When taken correctly under the tongue, naloxone has limited effect.

The most important practical difference is that the products are formulated differently. This can affect how much buprenorphine is absorbed, how the tablet or film is used, and which strengths are available. A person should take only the exact product and dose prescribed; one medicine should not be substituted for the other without clinician instructions.

Feature	Zubsolv	Suboxone
Active ingredients	Buprenorphine and naloxone	Buprenorphine and naloxone
Form	Sublingual tablet	Sublingual film
How it is taken	Placed under the tongue to dissolve	Placed under the tongue or inside the cheek, depending on prescriber instructions
Absorption	Different formulation and bioavailability	Different formulation and bioavailability
Dose conversion	Requires product-specific clinical guidance	Requires product-specific clinical guidance
Common role	Maintenance treatment for OUD	Maintenance treatment for OUD

Neither medication is inherently “better” for every person. The appropriate choice is the one that safely controls withdrawal and cravings, fits the person’s treatment plan, and can be taken consistently as directed.

What these medicines do in opioid use disorder

Opioid use disorder is a medical condition in which continued opioid use becomes difficult to control despite harm or distress. It may involve prescription opioid pain medicines, heroin, fentanyl, or other opioids. Evidence-based treatment can reduce withdrawal, cravings and the risk of returning to unregulated opioid use.

Buprenorphine is a partial opioid agonist. This means it activates opioid receptors enough to relieve withdrawal and cravings but has a ceiling effect on some opioid effects. Naloxone is an opioid antagonist. It is added to combination products primarily as a safety feature because it can trigger withdrawal if a medicine is dissolved and injected by someone dependent on opioids.

Medication treatment is not simply replacing one drug with another. When prescribed and monitored appropriately, buprenorphine-based treatment is a recognized medical approach that can support stability, functioning and recovery. It may be combined with behavioral therapy, mental health care, social support and treatment for related health conditions. More information about the underlying condition is available in opioid use disorder.

How a clinician tells Zubsolv and Suboxone apart

Clinicians begin by confirming exactly which product a person is taking. The names may sound similar, and both contain buprenorphine and naloxone, but the dosage form is a key clue: Zubsolv is a sublingual tablet, whereas Suboxone is commonly supplied as a dissolving film. The product name, strength on the package, prescribed directions and pharmacy record help prevent medication errors.

They also assess clinical response rather than relying only on a number printed on the package. Important questions include whether the person has withdrawal symptoms before the next dose, ongoing cravings, opioid use, nausea, constipation, headache, sleepiness, or difficulty using the formulation correctly. A change may be considered if the medicine is not meeting treatment goals or is causing troublesome effects.

Because the formulations are absorbed differently, equivalent treatment doses are not always identical in milligrams. If a switch is clinically appropriate, the prescriber uses approved product information, clinical judgment and close follow-up to select a starting conversion. A person should never cut, combine, double, or independently exchange tablets and films to try to create an equivalent dose.

• Medication history, including prior buprenorphine treatment
• Current withdrawal symptoms, cravings and opioid exposure
• Other medicines, especially sedatives or drugs that affect breathing
• Liver health, pregnancy status and coexisting mental health needs
• Ability to use and store the chosen formulation safely

What to do in common situations

If starting treatment: a qualified clinician should assess the type of opioid used, the timing of the last dose, withdrawal severity and overall health. Starting buprenorphine too soon after certain opioids can cause precipitated withdrawal, which is a sudden worsening of withdrawal symptoms. The safest starting approach depends on the opioid involved and should be individualized.

If already stable on one product: it is generally best to continue taking it exactly as prescribed and discuss any concerns at a scheduled review. A switch may be considered for practical reasons or side effects, but it should be planned. The person should bring their current medication package or a clear photo of the label to the appointment if there is uncertainty about the product or strength.

If symptoms are breaking through: withdrawal symptoms, cravings or a return to opioid use do not mean treatment has failed. They are important signals to contact the prescribing team promptly. The clinician can assess medication timing, adherence, interactions, stressors and whether the treatment plan needs adjustment.

If a dose is missed: the person should follow the instructions provided by their prescriber or pharmacist. They should not take extra doses to catch up unless specifically advised. After more than one missed dose, or after using opioids again, clinical advice is particularly important before restarting.

Safety, side effects and interactions

Possible side effects of buprenorphine-naloxone products include headache, nausea, constipation, sweating, mouth discomfort, dizziness, tiredness and sleep problems. Some effects improve as the body adjusts, but persistent or concerning symptoms should be discussed with the prescribing clinician. Good oral hygiene and regular dental care are sensible for people using medicines that dissolve in the mouth.

The most serious risk is slowed or difficult breathing, especially when buprenorphine is combined with alcohol, benzodiazepines, sleep medicines, sedating antihistamines, muscle relaxants or other opioids. People should tell every healthcare professional involved in their care about all prescription medicines, non-prescription products, supplements and substances they use.

Buprenorphine can still cause dependence, so stopping suddenly may lead to withdrawal. A clinician can provide a safer plan if treatment needs to be reduced or discontinued. Medication should be stored securely, out of reach of children and others, and never shared. Accidental exposure in a child is a medical emergency.

Supporting treatment beyond the medication

Effective OUD care is person-centered. Some people benefit from counseling that addresses triggers, trauma, anxiety, depression, chronic pain, family strain or practical difficulties such as housing and employment. Others may choose peer support, recovery coaching or family education. These supports are options, not a test of whether someone “deserves” medication.

A regular follow-up plan allows the care team to review symptoms, medication safety, goals and overall wellbeing. Testing may sometimes be used to guide care, but it should be part of a respectful therapeutic relationship. The goal is to make treatment safer and more effective, not to punish a person for a health condition.

People who have experienced an opioid overdose, or who may witness one, can ask a clinician or pharmacist about naloxone rescue medication and overdose response planning. It is also important to seek help for infections, pain, mental health symptoms or pregnancy care without delaying because of worries about stigma.

When to seek medical care

Urgent medical help is needed for slow, shallow or stopped breathing; inability to wake a person; blue or gray lips; severe confusion; or suspected overdose. Call local emergency services immediately. If naloxone rescue medication is available, use it according to its instructions while awaiting emergency help.

Contact the prescribing clinician promptly for severe or persistent vomiting, fainting, marked sleepiness, new confusion, signs of an allergic reaction, worsening withdrawal, strong cravings, or opioid use after a period of stability. Pregnant people and those planning pregnancy should also contact their obstetric and addiction care teams promptly, since treatment should be coordinated rather than stopped abruptly.

For planned assessment and ongoing care, Acıbadem Health Point’s multidisciplinary specialists at JCI-accredited hospitals can evaluate opioid use disorder and develop individualized treatment plans for international patients. The appropriate service should always be selected with a qualified clinician, particularly when changing between Zubsolv and Suboxone.

Frequently asked questions